Compass Therapeutics (NASDAQ:CMPX) Upgraded at Leerink Partnrs

Compass Therapeutics (NASDAQ:CMPX) was upgraded by investment analysts at Leerink Partnrs from a “hold” rating to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports.

Several other equities research analysts have also commented on the stock. D. Boral Capital reiterated a “buy” rating and issued a $32.00 price objective on shares of Compass Therapeutics in a research report on Tuesday. Guggenheim reiterated a “buy” rating and set a $12.00 price objective on shares of Compass Therapeutics in a research note on Wednesday. Wedbush reiterated an “outperform” rating and set a $8.00 price target on shares of Compass Therapeutics in a research report on Tuesday. Jefferies Financial Group raised their target price on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, February 10th. Finally, Piper Sandler initiated coverage on Compass Therapeutics in a research report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 price objective for the company. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $11.63.

Compass Therapeutics Price Performance

CMPX stock opened at $1.69 on Tuesday. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $4.08. The business has a 50 day simple moving average of $2.81 and a 200-day simple moving average of $2.11. The firm has a market capitalization of $233.70 million, a PE ratio of -4.57 and a beta of 1.19.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). On average, equities research analysts expect that Compass Therapeutics will post -0.36 EPS for the current year.

Hedge Funds Weigh In On Compass Therapeutics

Several large investors have recently added to or reduced their stakes in CMPX. Tower Research Capital LLC TRC increased its stake in shares of Compass Therapeutics by 298.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock worth $25,000 after purchasing an additional 12,917 shares during the last quarter. Independent Advisor Alliance bought a new position in Compass Therapeutics in the fourth quarter valued at $26,000. BNP Paribas Financial Markets bought a new stake in Compass Therapeutics in the 4th quarter worth approximately $27,000. Intech Investment Management LLC purchased a new position in Compass Therapeutics in the 3rd quarter worth $30,000. Finally, Mariner LLC purchased a new stake in Compass Therapeutics during the 4th quarter valued at about $30,000. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.